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Objective: Thrombin and hypoxia each target human endometrial stromal cells (HESCs) to mediate long-acting progestin-only contraceptive
(LAPC)-induced abnormal uterine bleeding (AUB). Thus, the secretome resulting from treatment of primary cultures of HESCs with
thrombin or hypoxia was screened by mass spectrometry (MS) to detect potential protein mediators that lead to AUB.
Study design: Cultured HESCs were primed with estradiol±medroxyprogesterone acetate (MPA) or etonogestrel (ETO), the respective
progestins in MPA-injected and ETO-implanted LAPCs, and then treated by incubation with thrombin or under hypoxia. Collected
conditioned medium supernatants were used for protein identification and quantitation of potential AUB mediators by liquid chromatography
combined with tandem mass spectrometry analysis. Microarray analysis of parallel cultures and immunostaining of endometrial biopsies of
LAPC users vs. nonusers corroborated MS results.
Results: MS identified several proteins displaying changes in expression levels from either thrombin or hypoxia treatments that are integral
to angiogenesis or extracellular matrix formation. Several MS-identified proteins were confirmed by mRNA microarray analysis.
Overexpressed stanniocalcin-1 (STC-1) was observed in endometrium of LAPC users. Unlike controls, all LAPC users displayed endometrial
tubal metaplasia (ETM).
Conclusions: MS analysis identified many proteins that can affect angiogenesis or vessel integrity, thereby contributing to AUB.
Confirmation of STC-1 overexpression in LAPC users and microarray data supports the validity of the MS data and suggests STC-1
involvement in AUB. The discovery of ETM in LAPC users indicates that LAPC-related side effects extend beyond AUB. The results
presented here demonstrate a complex biological response to LAPC use.
Implications: MS identified several HESC secreted proteins deregulated by thrombin and hypoxia that may mediate LAPC-induced AUB.
The revelation of overexpressed STC-1 by combined in vivo and in vitro observations identifies a potential target for future studies to prevent
or minimize LAPC-induced AUB.
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Long-acting progestin-only contraceptives (LAPCs) are
recommended for use when estrogen-containing formula-
tions are contraindicated (e.g., during lactation and for
women at risk for thrombosis). They are generally safe,
inexpensive and effective, making them ideal for worldwideess article under the CC BY-NC-ND license (http://creativecommons.org/
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bleeding (AUB), a source of inconvenience, annoyance and
a religious taboo, explains the high discontinuation rate of
these inexpensive and effective contraceptives. Such AUB
accounts for half of discontinuations during the first year of
use and a 30% 5-year discontinuation rate [1].
Unlike menstrual bleeding, which originates primarily
from spiral arteries and arterioles in response to circulating
progesterone withdrawal, LAPC-induced AUB occurs
sporadically and transiently from focally distributed, struc-
turally compromised, dilated and fragile endometrial micro-
vessels [2]. Previously, we demonstrated that LAPC users
experience (a) reduced uterine blood flow accompanied by
hypoxia/reperfusion and reactive oxygen species generation
[3,4] and (b) increased expression by decidualized human
endometrial stromal cells (HESCs) of tissue factor, a 47-kDa
transmembrane protein that promotes hemostasis via throm-
bin generation [2,5]. Thrombin also induces gene transcrip-
tion by binding to protease-activated receptors expressed on
the surface of various endometrial cell types [6,7].
In cultured HESCs, hypoxia and thrombin each enhance
expression of angiogenic factors such as vascular endothelial
cell growth factor (VEGF) and interleukin-8 (IL-8) [8,6]. IL-
8 also recruits and activates neutrophils and natural killer
(NK) cells [6]. A corresponding increase in VEGF and IL-8
expression as well as excess neutrophil and NK cell
infiltration are reported in endometrial sections from LAPC
users [8]. The combined effects of this hyperangiogenic state
coupled with neutrophil and NK cell-derived proteases and
thrombin-enhanced matrix metalloproteinase (MMP) ex-
pression in HESCs are expected to damage the microvascu-
lar support structure to promote AUB [9].
To gain further insight into the consequences of LAPC
use on the endometrium, the effects of mediators of AUB,
i.e., hypoxia and thrombin, were evaluated on primary
cultures of HESCs during coincubation with medroxypro-
gesterone acetate (MPA) or etonogestrel (ETO), the
progestin components of LAPC formulations. Liquid
chromatography was used in combination with tandem
mass spectrometry (LC-MS/MS) to screen for the presence
of novel potential protein mediators of AUB secreted by
HESCs following incubation with thrombin or under
hypoxia. Assessment of steady-state levels of specific
mRNAs identified by microarray analysis in cultured
HESCs and of corresponding protein expression by
immunohistochemical analysis of endometrial biopsies
from LAPC users corroborated LC-MS/MS results.2. Materials and methods
2.1. Study participants and sample collection
The endometrial biopsies (n=8) were obtained from
women 3 months post-MPA administration after receiving
written informed consent at New York University under
institutional review board approval. Control endometriumbiopsies (n=4), all from the late secretory phase, were
obtained from the Yale pathology department with approval
by the Yale Human Investigations Committee. HESCs (n=3)
were isolated from endometrial biopsy specimens from
healthy females who underwent tubal sterilization after
receiving written informed consent under approval by the
Yale Human Investigations Committee. All the subjects
were cycling regularly and had not received hormonal
therapy for at least 3 months before surgery. These samples
were transported to Ohio State University under a material
transfer agreement with Yale University.
2.2. Cell culture
HESCswere isolated as previously described [10]. Aliquots
were thawed as needed and decidualized in serum-containing
medium with 10−8 M estradiol (E2) or E2+10−7 M of MPA
or ETO in 24-well cell culture plates as previously described
[11]. The cell monolayers were washed 4× with phosphate-
buffered saline to eliminate traces of serum for LC-MS/MS
analysis and incubated in serum-free defined medium
[DMEM/F12+5 μm FeSO4, 50 μm ZnSO4, 1 nm CuSO4,
50 μg/ml ascorbic acid (Sigma Chemical Co., St. Louis, MO,
USA) and 50 ng/ml EGF (BD Biosciences, Bedford, MA,
USA)] containing 10−8 M E2 or E2+10−7 M MPA or ETO±
1 U/ml human alpha-thrombin (Sekisui Diagnostics, Stam-
ford, CT, USA) for 24 h or ±48 h hypoxia (0.2% O2, 5% CO2
and 94.8% N2) as previously described [11]. For hypoxia, a
specialized hypoxia system produced by BioSpherix, Ltd
(Lacona, NY, USA) was used consisting of a 2-shelf
C-Chamber using the BioSpherix ProOx C21 Oxygen and
Carbon Dioxide Controller. Regular maintenance and calibra-
tion of the oxygen and carbon dioxide sensors were performed
routinely using certified, premixed gases.When necessary, the
sensors and sampling pump were replaced and the system was
recalibrated. For normal operation to maintain a hypoxic
environment, 100% nitrogen and 100% carbon dioxide gases
were used. Following the hypoxia or thrombin treatments,
collected conditioned media supernatant (CMS) was centri-
fuged for 5 min at 2000g and then for 10 min at 6000g before
further processing for LC-MS/MS.
2.3. Mass spectrometry
Following the hormone priming and hypoxia or thrombin
treatments of (n=1 patient) HESCs, 80 μl CMS+16 μl of
100 mM NH3HCO3+300 ng trypsin (#V511A; Promega,
Madison, WI, USA) was incubated overnight at 37°C and
dried, and 20 μl of 2% acetonitrile and 0.1% formic acid was
added. The generated peptide samples (4–6 μl) were diluted
in 16 μl of 2% acetonitrile in 0.1% formic acid and 18 μl
was analyzed by LC-MS/MS with a Thermo Scientific Easy-
nLC II (Thermo Scientific, Waltham, MA, USA) coupled to
a hybrid Orbitrap Elite ETD (Thermo Scientific, Waltham,
MA, USA) mass spectrometer using an instrument config-
uration as previously described [12]. In-line desalting was
accomplished using a reversed-phase trap column
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resin; Michrom Bioresources, Auburn, CA, USA) followed
by peptide separations on a reversed-phase column
(75 μm×250 mm) packed with Magic C18AQ (5 μm,
100 Å resin; Michrom Bioresources, Auburn, CA, USA)
directly mounted on the electrospray ion source. A 90-min
gradient from 7% to 35% acetonitrile in 0.1% formic acid at
a flow rate of 300 nl/min was used for chromatographic
separations. A spray voltage of 2000 V was applied to the
electrospray tip and the Orbitrap Elite instrument was
operated in the data-dependent mode, switching automati-
cally between mass spectrometry (MS) survey scans in the
Orbitrap (AGC target value of 1,000,000, resolution of
240,000 and injection time of 250 ms) with MS/MS spectra
acquisition in the linear ion trap (AGC target value of 10,000
and injection time of 100 ms). The 20 most intense ions from
the Orbitrap full scan were selected for fragmentation in the
linear ion trap by collision-induced dissociation with
normalized collision energy of 35%. Selected ions were
dynamically excluded for 30 s. Mass Matrix database search
software was used to determine peptide/protein identity and
protein matches were retained based on a false discovery rate
of 5% and presence of two unique peptide matches.
Differences in peptide abundances are corrected by normal-
izing each sample geometric mean of the 50 most highly
detected peptide counts. Student's t test used normalized
counts to calculate statistical significance of pair-wise
comparisons. Each calculation is performed in the R statistical
computing/graphics environment (http://www.r-project.org).
2.4. Microarray analysis
Total RNA was extracted from cultured HESCs (n=3
patients) using RNeasy Mini and RNeasy MinElute Cleanup
Kits (Qiagen, Valencia, CA, USA). RNA quality was
initially determined by examining the 260/280 ratio.
Subsequently, use of a bioanalyzer confirmed the quality
of the RNA by assessing the 20S and 18S RNA peaks.
Extracted mRNA was analyzed using Illumina Human HT-
12 v4 Expression BeadChip (Illumina Inc., San Diego, CA,
USA). Raw data without normalization were analyzed by
GeneSpring GX12.5 software (Agilent Technologies Silicon
Genetics, Redwood City, CA, USA). Gene readouts were
normalized to the 75th percentile of the distribution of all
measurements in each chip. Normalization/per-gene across
chips used the median value of each gene throughout
different chips in the same experimental condition. Normal-
ized data were initially filtered to eliminate genes absent in
all experimental treatments then filtered on volcano plots
with moderated t test without multiple testing correction.
Genes with a fold change of N1.25 and a p value of b .05
were considered differentially expressed.
2.5. Immunohistochemistry
Immunostaining for stanniocalcin-1 (STC-1) on endome-
trial sections from LAPC users vs. nonusers was performedas previously described [11]. Briefly, following deparaffini-
zation in xylenes and incubation in ethanol and water,
samples were briefly heated to 100°C in citric acid allowed
to cool 5 min and reheated 3 times. After cooling, slides
were rinsed in Tris-buffered saline with 0.1% tween-20
(TBS-T) and incubated in 3% H2O2 and 50% MeOH for
12 min at room temperature followed by washing in TBS-T.
Sections were blocked for 30 min at room temperature with
5% goat serum in TBS-T and rabbit IgG anti-STC-1 diluted
1:600 (Novus Biologicals, Littleton, CO, USA) or control
rabbit IgG at the same concentration in 1% goat serum in
TBS-T added for overnight incubation at 4°C. Slides were
washed in TBS-T and incubated with biotinylated goat
antirabbit IgG (Vector Laboratories, Burlingame, CA, USA)
in TBS-T for 30 min at room temperature. Immunoreactivity
was developed using biotinylated antirabbit IgG, streptavi-
din–biotin peroxidase complex (Elite ABC kit PK-6200) and
peroxidase substrate kit (sk-4100) (Vector Labs, Burlin-
game, CA, USA). Slides were then slightly counterstained
with hematoxylin. HSCOREs were performed examining
combined STC-1 expression in stromal, epithelial and
endothelial cells.3. Results
LC-MS/MS analysis of HESC-derived CMS identified an
average of 400 proteins per sample. As previously reported,
the number of peptides (peptide counts) detected by LC-MS/
MS for a specific protein is proportional to its quantity in an
analyzed sample [13,14]. Statistical analysis of peptide
counts from the HESC-derived secretome revealed 69 and 42
proteins that demonstrated significant changes (pb.05)
following thrombin treatment or incubation under hypoxia,
respectively. The volcano plots in Fig. 1 display fold change
in peptide counts (represented on the x-axis as log base 2
ratio of the normalized peptide counts) against magnitude of
p values (represented on the y-axis as negative log base 10 of
p values obtained from the Student's t test) for individual
proteins identified by the LC-MS/MS. Peptides that show
significant changes (pb.05) after thrombin or hypoxia
treatments are marked in red. Hypoxia and thrombin each
induced both up-regulation and down-regulation of several
proteins. Compared to the control incubation in which no
peptides were detected for STC-1, experimental incubations
either under hypoxia or with thrombin show marked
increases of 11 (pb.05) and 15 (p=.076) peptide counts on
average, respectively, noted as squares on the volcano plots.
Finally, the LC-MS/MS peptide counts of the hormone-
primed (i.e., E2, E2+MPA or E2+ETO) HESCs following
thrombin or hypoxia treatment vs. controls were similar for
the proteins demonstrating significant changes and shown in
red on the volcano plots.
Tables 1 and 2 display normalized peptide counts and
mRNA fold change for proteins shown to be either regulated





































Fig. 1. Volcano plots of MS generated peptide count data. Each point on the plots represents the comparison of peptide counts of an individual protein (identified
by the MS) of hormone-treated control cells vs. same hormone treatments following incubation with thrombin or hypoxia. Student's t test was used on
normalized peptide counts to calculate statistical significances of pair-wise comparisons of control with E2, E2+MPA and E2+ETO vs. the same treatment with
thrombin or hypoxia. The data are from log base 2 of the fold changes in peptide counts vs. negative log base 10 of the p values. Panel A shows proteins that were
either up- or down-regulated from thrombin treatment with significant differences (pb.05) indicated in red. Panel B shows proteins either up- or down-regulated
following hypoxia with significant differences (pb.05) indicated in red. STC-1 is indicated by square.
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tables. Table 1 lists peptide counts from proteins that were
found by LC-MS/MS to be regulated by thrombin or hypoxia
with a p value of b .05, with the exception of thrombin
treatment resulting in a p value of .076 for STC-1 expression.
The mRNA fold changes for specific proteins found to be
either regulated by thrombin or hypoxia corroborate the
direction of change in protein expression detected by
LC-MS/MS. Following thrombin treatment of HESCs,
three proteins — STC-1, chondroitin sulfate proteoglycan
4 (CSPG4) and cysteine-rich angiogenic inducer 61able 1
eptide counts of proteins with enhanced expression following thrombin or hypoxiaT
P(Cyr61) — demonstrated significant changes (pb.05) in
mRNA expression levels, thus confirming changes in protein
levels detected by LC-MS/MS. Following incubation under
hypoxia, microarray analysis corroborated the changes
detected by LC-MS/MS for the expression of STC-1 as
well as insulin-like growth factor-binding protein 3
(IGFBP3). Examination of the unregulated (stable) peptide
counts shown in Table 2 demonstrates the capability of LC-
MS/MS to discriminate among proteins present at relatively
high, medium or low expression levels. No changes in
mRNA levels were seen for these proteins in comparisons
Table 2
Peptide counts of proteins unchanged following thrombin or hypoxia
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peptide counts of calumenin (Table 2) and MMP10
(Table 1), the incubations with E2 vs. E2 plus either MPA
or ETO indicate an independent progestin effect on
thrombin- or hypoxia-treated HESCs for both proteins.Fig. 2. (A) STC-1 staining of representative endometrial biopsy sections from a
Arrowheads (insets) point to cilia on epithelial surface (bottom inset) or intense
formulation LAPC user showing cilia (arrowhead) on epithelium of gland. Inset sh
bar represents 15 μm. (C) STC-1 staining of non-LAPC user showing surface e
represents 50 μm for panels A, B and C. (D) H-scoring of n=8 MPA formulationAmong several proteins observed to be regulated by
incubation with either thrombin or under hypoxia shown in
Table 1, STC-1 expression alone is enhanced during
incubations with both thrombin and hypoxia. Additionally,
no peptides were detected for STC-1 for the controls for bothn MPA formulation LAPC user. Scale bar in the inset represents 15 μm.
STC-1 staining of nuclear bodies (top inset). (B) STC-1 staining of MPA
ows endometrial staining following incubation with control IgG where scale
pithelium (arrow), stroma (Str) and gland (arrowhead). Scale bars shown
LAPC users vs. n=4 of nonusers (pb.001).
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as a stimulus to perform STC-1 immunostaining on LAPC-
derived endometrial biopsies obtained from women using
the LAPC formulation, MPA vs. nonusers. In Fig. 2A,
endometrial tissue obtained from a representative MPA
LAPC user displays epithelial and stromal cell cytoplasmic
and nuclear staining for STC-1 as well as darker-stained
nuclear bodies in stromal cells (arrowhead, upper inset).
STC-1 nuclear immunostaining staining has been previously
observed [15] and the staining of nuclear bodies observed
here has been described by others in nuclei of leukemic cell
lines [16]. The presence of cilia on the luminal epithelium
(Fig. 2A) of the MPA LAPC user indicates endometrial tubal
metaplasia (ETM). This observation was confirmed in all of
the treated patients examined (n=8), whereas ETM was not
detected in four control endometria that were all in the late
secretory phase of the menstrual cycle at the time of biopsy
collection. The luminal epithelial surface of endometrial
glands in MPA LAPC users also displayed cilia (Fig. 2B).
Fig. 2C shows light STC-1 staining of non-LAPC users. The
HSCOREs (Fig. 2D) demonstrates significant difference in
STC-1 staining between MPA LAPC users vs. nonusers
(pb.001).4. Discussion
Downstream LAPC effects were evaluated in primary
cultured HESCs. Specifically, the cells were primed with E2
or E2+MPA or E2+ETO±thrombin or under hypoxia, to
mimic the endometrial milieu induced by LAPCs. The
resulting secretome was interrogated by LC-MS/MS to
screen for potential mediators of AUB in the conditioned
medium supernatants of HESCs obtained from a single
patient. Statistical analysis of LC-MS/MS-generated peptide
counts from HESC-derived CMS identified several signif-
icantly regulated proteins in response to either hypoxia or
thrombin. The presence of numerous proteins with stable
peptide counts indicates that peptide count numbers for
regulated proteins do not reflect random data acquisition by
LC-MS/MS.
In conjunction with the MS study, HESCs from n=3
patients were (hormone) primed and then treated with
thrombin or under hypoxia and mRNA microarray analysis
was performed on the isolated RNA. The statistical
characterization of the mRNA microarray analysis was
used in conjunction with the MS peptide count data to select
a target for characterization of endometrial biopsies from
LAPC users vs. nonusers using immunohistochemistry
(IHC) analysis. Both thrombin and hypoxia induced
substantial increases in the number of peptides for STC-1,
whereas no peptides were detected for their respective
controls by LC-MS/MS analysis. The microarray results
corroborated the effect of thrombin and hypoxia on STC-1
expression. Additionally, all other common proteins identi-fied in the microarray data corroborated the analysis of the
peptide count MS data.
The current study identified several proteins found to be
regulated by hypoxia or thrombin previously reported to
influence angiogenesis as well as extracellular matrix (ECM)
and vascular integrity. Among thrombin-induced proteins
secreted by HESCs are several that are involved in
angiogenesis and/or vessel formation. Specifically, these
include (1) mediators of angiogenesis or vessel formation
such as Cyr61 [17], STC-1 [18] and CSPG4 [19]; (2)
mediators of ECM formation/degradation such as MMP10
[20] and MMP2, which can effect vessel formation [21] and,
finally, (3) emilin-1, an ECM reported to affect vessel
integrity [22]. Two of the HESC secreted proteins affected
by hypoxia also are also known to modulate angiogenesis.
These include IGFBP3, a potent mediator of tube formation
[23] and STC-1. Taken together, the results confirm that
LAPC use induces a complex response that may trigger
AUB. A recent study using LC-MS/MS to examine the
secretome of glioma cells incubated under hypoxia found
that both IGFBP3 and STC-1 are significantly up-regulated
and that their expression is highly correlated with glioma
grade [24].
Microarray analysis demonstrated that thrombin and
hypoxia each induce changes in HESC-derived steady-state
mRNA levels that parallel the LC-MS/MS observations.
Although all proteins showed the same directional change in
mRNA levels, only for STC-1 were steady-state peptide
counts and mRNA levels up-regulated by both thrombin and
hypoxia. STC-1 was originally discovered in bony fish as a
secreted product of the corpuscles of Stannius, an endocrine
organ involved in Ca2+ homeostasis [25]. As described
above, STC-1 has been reported to be involved in
angiogenesis. Specifically, this includes activity in affecting
tube formation [18], promoting angiogenic sprouting of
cultured human umbilical vein endothelial cells [26] and
decreasing production of vascular endothelial growth factor
(VEGF) [27], the primary mediator of angiogenesis [28].
Moreover, STC-1 is highly expressed in small vessels in
colon adenocarcinomas [29]. Other studies from our
laboratory indicate that LAPC-induced AUB involves
endometrial hyperangiogenesis suggesting that local STC-
1 expression may be a contributing factor to such AUB.
Other cellular effects exerted by STC-1 likely to be involved
in the occurrence of AUB include (1) increased mitochon-
drial electron transport chain activity and calcium transport
[30], (2) inhibition of apoptosis [31] and (3) protection
against hypoxia-induced superoxide generation [32].
Recently, STC-1 mRNA overexpression was described in
placentas associated with small- and large-for-gestational-age
deliveries and gestational diabetes as well as preeclampsia
with elevated STC-1 plasma levels accompanying pre-
eclampsia [33].
STC-1 immunostaining observed in several endometrial
cell types in AUB patients vs. control endometrial sections in
the current study strengthens the link between aberrant
259J.P. Shapiro et al. / Contraception 91 (2015) 253–260endometrial STC-1 expression and the onset of AUB. IHC
confirmation of the STC-1 MS and microarray findings
support the need for further study of the array of proteins
shown here to be dysregulated by thrombin and hypoxia. The
expression of STC-1 on ETO LAPC user endometrial
biopsies was not examined during this study due to sample
unavailability. However, the similarity of the MS and
microarray findings for the array of dysregulated proteins
described here from the MPA- and ETO-primed HESCs
suggests that a similar outcome would be observed on the
endometrium of an ETO LAPC user. However, future
studies are necessary to confirm this supposition.
These observations stress the importance of integrating in
vitro observations in which LC-MS/MS is used to search for
novel potential mediators of AUB with immunostaining of
those proteins in LAPC-derived endometrial sections.
Despite the small sample size of the LC-MS/MS data
described in this study, these results serve as proof-of-
concept for effective utilization of LC-MS/MS to identify
proteins with changes in expression levels. Moreover, the
unexpected revelation that LAPC use in women is
accompanied by ETM, which is induced in human
endometrium as a result of “hormone irritation” [34],
indicates that as has been discussed in a recent comprehen-
sive review [35], the side effects of LAPC use are not limited
to the occurrence of AUB.
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